Objective To prepare a novel imaging agent of 131I-SAP targeting amyloidosis, and evaluate its security for further clinical application. Methods Standard sample of SAP was radiolabeled with 131I by Iodogen method. The labeling efficiency and radiochemical purity of 131I -SAP were calculated by the paper chromatography. The in vitro stability of 131I-SAP under different conditions(4 ℃ and 37℃) were determined at 0, 24, 48, 72 and 96 h respectively. Pyrogen and toxicity tests were also performed. Results The labelingefficiencies of 131I-SAP reached 70.6%, and the radiochemical purity was above 90% at 96 hours. The safety experiments showed that 131I-SAP was free of pyrogen and toxicity. Conclusion 131I-SAP is stable in vitro, and free of pyrogen and toxicity, which may be suitable for further clinical application.
WEI Hai-liang
,
YAN Ping
,
ZHANG Jian-hua
,
LIU Meng
,
KANG Lei
,
ZHANG Li
,
GUO Feng-qin
,
ZHANG Chun-li
,
WANG Rong-fu
. Preparation of 131I-SAP and Evaluation of Its Safety forFurther Clinical Application[J]. Labeled Immunoassays and Clinical Medicine, 2013
, 20(3)
: 179
-181
.
DOI: 10.11748/bjmy.issn.1006-1703.2013.03.018
[1] Pepys M B, Booth D R, Hutchinson W L, et al. Amyloid P component. A critical review[J]. Amyloid:The Journal of protein folding disorders,1997, 4(4):274-295.
[2] Tennent G A, Dziadzio M, Triantafilidou E, et al. Normal circulating serum amyloid P component concentration in systemic sclerosis[J]. Arthritis Rheum,2007,56(6):2013-2017.
[3]Hawkins P N, Myers M J, Epenetos A A, et al. Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component[J]. J Exp Med,1988,167(3):903-913.
[4] Hazenberg B P, van Rijswijk M H, Piers D A, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis[J]. Am J Med,2006,119(4):355.e15-e24.
[5]Hawkins P N, Aprile C, Capri G, et al. Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis[J]. Eur J Nucl Med, 1998,25(7):701-708.
[6]魏海亮,张春丽,王荣福,等.碘标记血清淀粉样P成分在动物模型中的体内分布及显像研究[J].中华核医学杂志,2011, 31(6):410-413.
[7] Schaadt B K, Hendel H W, Gimsing P, et al. 99 Tc m -Aprotinin scintigraphy in amyloidosis [J]. J Nucl Med, 2003, 44(2):177-183.
[8]Eguchi M, Takizawa H, et al. Detection of cardiac calcinosis in hemodialysis patients by whole body scintigraphy with 99m-Technetium methylene diphosphonate[J]. Am J Nephrol, 2000, 20(4): 278-282.
[9]Kazama J J, Arakawa M, Gejyo F. Synovial inflammatory cells captured 131I-beta 2-microglobulin in patients with dialysis related amyloidosis[J]. Amyloid, 1998, 5(1):24–29.
[10]Dezutter N A, Landman W J, Jager P L. Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis[J]. Amyloid, 2001, 8(3):202-214.
[11] Botto M, Hawkins P N, Bickerstaff MC, et al. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene[J]. Nature Med, 1997, 3(8):855-859.
[12] Hachulla E,Grateau G. Diagnostic tools for amyloidosis[J]. Joint Bone Spine,2002,69(6):538-545.
[13] Bodin K,Ellmerich S,Kahan M C,et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits[J].Nature,2010,468(7320):93-97.
